Autism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Autism - Pipeline Review, H2 2016

Autism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Autism - Pipeline Review, H2 2016
Published Jul 27, 2016
134 pages — Published Jul 27, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Autism - Pipeline Review, H2 2016, provides an overview of the Autism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Autism therapeutics and enlists all their major and minor projects
- The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Autism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Autism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners w

  
Source:
Document ID
GMDHC8306IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Autism Overview101
Therapeutics Development112
  Pipeline Products for Autism Overview111
  Pipeline Products for Autism Comparative Analysis121
Autism Therapeutics under Development by Companies133
Autism Therapeutics under Investigation by Universities/Institutes161
Autism Pipeline Products Glance174
  Late Stage Products171
  Clinical Stage Products181
  Early Stage Products191
  Unknown Stage Products201
Autism Products under Development by Companies212
Autism Products under Investigation by Universities/Institutes231
Autism Companies Involved in Therapeutics Development2420
  Addex Therapeutics Ltd241
  Aequus Pharmaceuticals Inc.251
  AgeneBio Inc.261
  APeT Holding BV271
  BioCrea GmbH281
  BrainStorm Cell Therapeutics Inc.291
  Cellceutix Corporation301
  Confluence Pharmaceuticals LLC311
  Coronis Partners Ltd.321
  Curemark, LLC331
  F. Hoffmann-La Roche Ltd.341
  GW Pharmaceuticals Plc351
  Heptares Therapeutics Limited361
  Intra-Cellular Therapies, Inc.371
  MedDay SA381
  Omeros Corporation391
  Otsuka Holdings Co., Ltd.401
  Retrophin Inc.411
  Saniona AB421
  Sumitomo Dainippon Pharma Co., Ltd.431
Autism Therapeutics Assessment4412
  Assessment by Monotherapy Products441
  Assessment by Combination Products451
  Assessment by Target463
  Assessment by Mechanism of Action493
  Assessment by Route of Administration522
  Assessment by Molecule Type542
Drug Profiles5667
  (dextromethorphan + quinidine sulfate) Drug Profile565
  acamprosate calcium Drug Profile611
  ACT-01 Drug Profile621
  ADX-71441 Drug Profile633
  ADX-88178 Drug Profile662
  aripiprazole Drug Profile684
  aripiprazole Drug Profile722
  carbetocin Drug Profile741
  CB-0306 Drug Profile751
  CM-AT Drug Profile762
  Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome Drug Profile781
  GWP-42006 Drug Profile792
  histamine dihydrochloride Drug Profile811
  HTL-14242 Drug Profile821
  ITI-007 Drug Profile838
  KM-391 Drug Profile911
  lurasidone hydrochloride Drug Profile927
  MD-1103 Drug Profile991
  niacinamide CR Drug Profile1001
  NurOwn Drug Profile1019
  oxytocin Drug Profile1101
  RG-7314 Drug Profile1111
  SF-999 Drug Profile1121
  Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism Drug Profile1131
  Small Molecule to Agonize GABRA5 Receptor for CNS Disorders Drug Profile1141
  Small Molecule to Block Chloride Channels for Autism Drug Profile1151
  Small Molecule to Target GPR63 for Autism Drug Profile1161
  Small Molecule to Target Oxytocin for Autism and Anxiety Disorders Drug Profile1171
  Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism Drug Profile1181
  Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome Drug Profile1191
  Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology Drug Profile1201
  Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure Drug Profile1211
  Synthetic Peptide for Autism and Alzheimer's Disease Drug Profile1221
Autism Dormant Projects1233
Autism Discontinued Products1261
Autism Product Development Milestones1276
  Featured News &Press Releases1271
    Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch1271
    Dec 07, 2015: Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism1271
    Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole1281
    May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism1281
    Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment1291
    Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt1291
    Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis1291
    Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz1301
    Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism1301
    Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors1301
    Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism1311
    May 31, 2012: Study Reports New Treatment For Irritability In Autism1311
    Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism1321
    Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism1321
    Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation1321
Appendix1332
  Methodology1331
  Coverage1331
  Secondary Research1331
  Primary Research1331
  Expert Panel Validation1331
  Contact Us1331
  Disclaimer1341

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Autism - Pipeline Review, H2 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Autism-Pipeline-Review-H2-2016-2088-16270>
  
APA:
Global Markets Direct - Market Research. (2016). Autism - Pipeline Review, H2 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Autism-Pipeline-Review-H2-2016-2088-16270>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.